Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMD 1201081 plus Cetuximab in R/M SCCHN
NCT01040832Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Dec 2009
- Primary completion
- Jan 2012
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 8
01
Overview
A Phase 2 trial of IMO-2055 in squamous cell carcinoma of the head and neck (HNSCC), sponsored by EMD Serono. Started Dec 2009; status: completed.
02
Drugs
IMO-2055
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01040832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01040832.